A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

[MEDPAGE TODAY]( Oncology Update Friday, July 12, 2024 [A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll]( [Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy]( [If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version]( [Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC]( [Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?]( ADVERTISEMENT Exclusives & Features [More Physicians at Washington Hospitals File to Unionize]( [These Six Specialties Have the Highest Rates of Burnout]( [New Name for Familiar Phenomenon: 'Administrative Harm']( Industry Clinic Ad Insights [What Will It Take to Deliver Both Health & Care in Oncology?]( [Unveiling Chemotherapy's Impact on Lung Cancer through Single-Cell Transcriptomics]( Background. Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and frequently affects non-smokers, especially women. It is characterized by a complex genetic... [READ MORE]( [Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.]( BACKGROUND: The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the... [READ MORE]( [Trends in breast cancer incidence by estrogen receptor status in the United States, 2004-2020.]( Divergent trends of breast cancer incidence by subtype have been reported in the United States and elsewhere; however, it remains unknown whether this trend has continued until the era of the... [READ MORE]( [Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in oesophageal adenocarcinoma tumours.]( INTRODUCTION: For patients with locally advanced oesophagogastric cancer, the standard of care in the UK is neoadjuvant chemotherapy (NAC) followed by surgery. Prehabilitation exercise can improve... [READ MORE]( [Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database-based study.]( BACKGROUND: In 2015, the US Food and Drug Administration approved nivolumab as the first immunotherapy for patients with advanced non-small cell lung cancer (NSCLC). However, population-based... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-07-12&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011